Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tiotropium and Salmeterol PK Study in COPD Patients

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00673478
First received: May 6, 2008
Last updated: April 30, 2014
Last verified: April 2014
  Purpose
The primary objective of this study is to characterize the pharmacokinetics (i.e. systemic exposure to tiotropium and salmeterol) of tiotropium qd + salmeterol qd or bid versus tiotropium qd and salmeterol bid following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD).

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Tiotropium+Salmeterol
Drug: Salmeterol
Drug: Tiotropium
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Official Title: A Randomised, Open-label, 4-way Crossover Study to Characterize the Pharmacokinetics, Safety and Efficacy of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and a Free Combination of Tiotropium Plus Salmeterol Following 4-week Treatment Periods in Patients With COPD.

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Area under the concentration-time curve (AUC0-∞ ) of tiotropium in plasma [ Time Frame: 16 weeks ]
  • Maximum measured concentration of tiotropium in plasma (Cmax) [ Time Frame: 16 weeks ]
  • Amount of tiotropium that was eliminated in urine (Ae0-8) from time point 0 to 8 hours post-inhalation [ Time Frame: 16 weeks ]
  • AUC0-∞ of salmeterol in plasma [ Time Frame: 16 weeks ]
  • Cmax salmeterol in plasma [ Time Frame: 16 weeks ]

Secondary Outcome Measures:
  • Area under the concentration time curve (AUCt1-t2) of tiotropium and salmeterol in plasma over the time interval t1 to t2 for time intervals 0 to 4, 0 to 6, and 0 to 8 hours after inhalation (AUC0-4, AUC0-6, and AUC0-8) [ Time Frame: 16 weeks ]
  • Time from dosing to the maximum concentration of tiotropium and salmeterol in plasma (tmax) [ Time Frame: 16 weeks ]
  • Terminal rate constant in plasma (λz) [ Time Frame: 16 weeks ]
  • Terminal half-life (t½) of tiotropium and salmeterol in plasma) [ Time Frame: 16 weeks ]
  • Mean residence time (MRTih) of tiotropium and salmeterol in the body after inhalational administration [ Time Frame: 16 weeks ]
  • Apparent clearance (CL/F) of tiotropium and salmeterol in plasma after extravascular administration) [ Time Frame: 16 weeks ]
  • Apparent volume of distribution (Vz/F) during the terminal phase (λz) following an extravascular dose) [ Time Frame: 16 weeks ]
  • Amount of tiotropium that is eliminated in urine from the time point t1 to time point t2 (Aet1-t2) (Ae0-2, Ae2-4, Ae4-8, Ae0-8) [ Time Frame: 16 weeks ]
  • Fraction of tiotropium eliminated in urine from time point t1 to time point t2 (fet1-t2) (fe0-2, fe2-4, fe4-8, fe0-8) [ Time Frame: 16 weeks ]
  • Renal clearance of tiotropium from the time point t1 until the time point t2 (CLR,t1-t2) (CLR,0-2, CLR, 2-4, CLR,4-8, CLR,0-8) [ Time Frame: 16 weeks ]
  • All adverse events [ Time Frame: 20 weeks ]
  • Blood pressure (seated) recorded in conjunction with 12-lead ECG recordings pre-dose and following the morning dose of randomized treatment [ Time Frame: 20 weeks ]
  • Number of patients with abnormalities in routine blood chemistry, haematology and urinalysis [ Time Frame: 16 weeks ]
  • Trough forced expiratory volume in one second (FEV1) [ Time Frame: 16 weeks ]
  • Trough forced vital capacity (FVC) [ Time Frame: 16 weeks ]
  • FEV1 area under the curve 0 to 8 hours (FEV1 AUC0-8h) [ Time Frame: 16 weeks ]
  • FVC area under the curve 0 to 8 hours (FVC AUC0-8h) [ Time Frame: 16 weeks ]
  • Individual FEV1and FVC measurements at each time point at the end of each 4-week treatment period. [ Time Frame: 16 weeks ]

Enrollment: 50
Study Start Date: May 2008
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

COPD patients of >= 40 years old with moderate to severe COPD who are current or ex-smokers with a smoking history of at least 10 pack-years

Exclusion Criteria:

  1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure
  2. History of asthma
  3. Malignancy requiring treatment within past 5 years
  4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis
  5. Known active tuberculosis
  6. Pregnant or nusing women
  7. Known hypersensitivity to components of the study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00673478

Locations
Belgium
1184.24.32001 Boehringer Ingelheim Investigational Site
Genk, Belgium
1184.24.32002 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
Netherlands
1184.24.31001 Boehringer Ingelheim Investigational Site
Heerlen, Netherlands
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00673478     History of Changes
Other Study ID Numbers: 1184.24
EudraCT 2007-000207-15
Study First Received: May 6, 2008
Last Updated: April 30, 2014

Additional relevant MeSH terms:
Lung Diseases
Chronic Disease
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Lung Diseases, Obstructive
Tiotropium Bromide
Salmeterol Xinafoate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents

ClinicalTrials.gov processed this record on May 24, 2017